StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
LIK.DE$505.00-1.94%
Fair $505.00+0.0%

LIK.DE

LIMES Schlosskliniken AG

Healthcare / Medical Care FacilitiesXETRA

$505.00

-10.00 (-1.94%)

Fairly Valued+0.0%Fair Value $505.00Fund rank 28/100 · Data gapFallback financials|
SA 61/B
F-Score: 7/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 33% · confianza 21%

FCF escenarios

weak_data · normalized FCF $1.1M · quality 45.3/100

Data gap 28/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 26/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

61/100

B

Piotroski

7/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · LIK.DELocal privado en este navegador · LIMES Schlosskliniken AG
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$150M

P/E

26.4x

↑

EV/EBITDA

11.8x

↓

ROE

22.5%

↑

Gross Margin

91.9%

↑

Debt/Equity

0.42

↑
52-Week Range$505
$316$530

TradingView lightweight chart

LIK.DE price, volumen y niveles de valoración

Último $505.00Periodo +393.7%
Fair value: $505.00

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+20.2%

FCF CAGR

-44.6%

FCF margin

2.3%

FCF / Net income

0.20x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $50.0M · net income $5.7M · FCF $1.1M

2022-FY → 2025-FY

Gross margin

91.9%+1.7% pts

Operating margin

18.6%+11.9% pts

Net margin

11.4%-3.2% pts

FCF margin

2.3%-21.0% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$50.0M$50.0M$37.5M$37.2M$28.8M
Net Income$5.7M$5.7M$3.1M$3.4M$4.2M
EBITDA$12.8M$12.8M$7.1M$7.7M$4.6M
EPS19.1119.1110.6111.5814.34
Gross Margin91.9%91.9%92.1%90.8%90.2%
Operating Margin18.6%18.6%11.5%13.5%6.7%
Net Margin11.4%11.4%8.3%9.1%14.6%
Balance Sheet
Debt/Equity0.420.420.570.670.81
Current Ratio4.134.13———
Cash Flow
Free Cash Flow$1.1M$1.1M$2.5M$-3.5M$6.7M
Returns
ROE22.5%22.5%17.0%22.5%37.9%
Valuation
P/E26.4326.4332.2325.5622.87
EV/EBITDA11.7911.7914.1611.5220.51
P/B5.945.945.475.748.66
Growth & Yield
Revenue Growth33.5%33.5%0.8%29.0%—
EPS Growth80.1%80.1%-8.4%-19.2%—
Dividend Yield1.9%1.9%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

32.9%

muy exigente

EPS terminal req.

$44.81

Spread vs growth

47.3%

5Y implied EPS CAGR

23.2%

exigente

EPS terminal req.

$54.22

Spread vs growth

56.9%

10Y implied EPS CAGR

16.4%

exigente

EPS terminal req.

$87.32

Spread vs growth

63.7%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +54.0%

Total return

+54.0%

Start / end P/E

31.3x → 26.4x

EPS bridge

10.61 → 19.11

Residual

-12.5%

EPS growth+80.1%
Multiple rerating-15.5%
Dividend+1.9%
Residual / FX / buybacks / cross-term-12.5%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.